Want to see GB:AVCT full AI Analyst Report?
AVCT Stock Chart & Stats
64.10 p
0.40 p(0.62%)
At close: 4:00 PM EDT
64.10 p
0.40 p(0.62%)
Day’s Range― - ―
52-Week Range41.33 p - 92.00 p
Previous CloseN/A
Volume605.24K
Average Volume (3M)3.07M
Market Cap
£304.46M
Enterprise Value342.34M
Total Cash (Recent Filing)£16.86M
Total Debt (Recent Filing)£14.92M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
On‑time Clinical ExecutionDelivering the first‑in‑human dose on schedule demonstrates operational execution and trial management capability. That execution lowers program risk, supports the planned late‑2026 readout timetable, and makes the company a more credible partner for licensing or co‑development discussions over the next 2–6 months.
Preclinical Differentiation Vs ADCsSubstantially higher tumor payload exposure and selectivity are durable technical advantages for the pre|CISION platform. This mechanistic differentiation can translate into better therapeutic index, stronger clinical differentiation and commercial appeal, underpinning longer‑term partner interest and licensing value.
Expanded IP & Dual‑payload CapabilityAn expanding IP estate and novel dual‑payload capability create a structural moat that supports exclusivity for differentiated product concepts. Robust IP protection increases bargaining power in partnerships and licensing, and preserves long‑term optionality across multiple payload and tumour‑targeting programs.
Bears Say
Eroding Balance Sheet And LeverageA shrinking equity base and reduced asset base materially weaken financial flexibility. Elevated leverage relative to equity increases dilution and refinancing risk, constrains the company's ability to self‑fund later‑stage trials, and limits strategic optionality absent partner funding or fresh capital raises.
Persistent Negative Operating And Free Cash FlowSustained cash burn with deeply negative free cash flow means the business consumes capital to advance R&D rather than generating it. This structural cash profile necessitates recurrent financing or partnering, increasing dilution risk and placing long‑term program continuity under pressure without external funding.
Dependence On Partnering For Pivotal DevelopmentRequiring a partner to initiate pivotal studies shifts control of critical development timelines and commercialisation to third parties. This reliance introduces execution and timing risk, potentially delaying value inflection points and making future revenue and profitability contingent on successful dealmaking rather than internal progress.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 41.33 p and its highest was 92.00 p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £304.46M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 53 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on May 19, 2026. The company reported -0.051 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.051 p.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.051 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.959%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―